A powerhouse partnership is taking shape in California’s Coachella Valley, where cannabis operator Green Horizons has signed a five-year master service agreement with FOHSE, a leader in high-performance cultivation lighting and technology. The strategic alliance signals a major step forward for scalable cannabis production, merging advanced engineering with a vision for industry-leading efficiency.

Under the agreement, FOHSE will become the exclusive lighting and technology provider for Green Horizons’ sprawling one-million-square-foot cannabis campus in Coachella. The deal kicks off with installation at the company’s 101,787-square-foot Phase I cultivation facility, where perimeter and under-canopy lighting will be implemented in Q3 2025.

Lighting the Way Forward

FOHSE—short for Future of Horticultural Science + Engineering—has earned a global reputation for innovation in LED technology tailored specifically for cannabis. With this new partnership, the company solidifies its role as a technology-first provider in a sector increasingly driven by precision and scale.

“We are very excited about our agreement with Green Horizons and being able to work so closely with them on the cultivation side,” said Ben Arnet, Co-Founder and President of FOHSE. “Our main goal is to increase yields, decrease cost per pound, and introduce more efficient technology specifically designed for cannabis cultivation.”

That technology is already being put to use. The current deployment at Green Horizons’ Phase I facility will help optimize growing conditions and drive operational efficiency, setting the stage for what both companies see as a transformative evolution in cannabis agriculture.

An Enterprise Vision Beyond the Plant

While plenty of lighting companies sought a piece of Green Horizons’ attention following the success of its Phase I rollout, FOHSE distinguished itself with its long-term, systems-based approach to cultivation.

“FOHSE is more than a lighting company. They are a technology company,” said Michael Meade, Co-Founder of Green Horizons. “Los and I see Green Horizons the same way. We’re elated at the partnership and the innovation to come.”

For Green Horizons CEO Carlos “Los” Arias, the partnership is about more than infrastructure—it’s a blueprint for the cannabis industry’s future. “Brett, Ben, and the entire FOHSE team are dream partners,” Arias said. “They have a global vision and understand what creates enterprise value beyond merely producing flower and selling it. This is a moment for the industry and we’re ready to rock this.”

Looking Ahead to “Black Label” Breakthroughs

With Phase I lighting installation underway, the partnership will expand in 2026 to Green Horizons’ Phase II facility—a high-tech “black label” greenhouse designed from the ground up. The new build will incorporate FOHSE’s next-gen lighting fixtures and Green Horizons’ proprietary evaporative cooling systems, aiming to achieve indoor-quality cannabis at a disruptive cost model.

This convergence of LED precision and climate control will further blur the lines between greenhouse and indoor cultivation, a critical advancement in a market increasingly focused on sustainability and ROI.

Scaling with Purpose

Green Horizons’ Coachella campus is among the most ambitious cultivation projects in North America, a purpose-built complex designed to address the growing demand for high-quality cannabis at scale. With an eye on compliance, environmental stewardship, and technological adoption, the company is crafting a model that could set the tone for the next decade of cannabis cultivation.

Meanwhile, FOHSE continues to dominate the horticultural lighting space, supplying some of the largest licensed cultivators in the world. The company’s emphasis on tailored engineering, energy efficiency, and performance-based solutions makes it a natural fit for operators seeking to scale responsibly.

As the industry braces for further consolidation and increased competition, the Green Horizons-FOHSE partnership offers a case study in what the future of cannabis production may look like: smart, efficient, and built to scale.

Source link

Medical Cannabis Awareness Week has expanded for 2025, with an entire month of momentum-building events and educational initiatives, as organisations in the sector mark seven years since the law change. 

Over the last few years, Medical Cannabis Awareness Week has become an important date in the diaries of many patients, activists and organisations in the sector.

First founded by the patient advocacy group PLEA (Patient-Led Engagement for Access) at the height of the Covid pandemic in 2020, it now takes place every November to mark the anniversary of the rescheduling of medical cannabis on 1 November, 2018. 

This year, the sector has gone a step further, celebrating Medical Cannabis Awareness Month, with over 30 organisations coming together to create awareness, dispel misinformation, and break down stigma through social media campaigns and in-person events.

It falls as the Advisory Council of the Misuse of Drugs is conducting a major review of the legislative framework around the prescribing of cannabis-based medicines, with stakeholders including clinics, producers, manufacturers, pharmacists, patient advocates, scientists and charities uniting to move the conversation forward. 

Here’s a quick look at the highlights so far, and what’s still left to look forward to. 

Lobbying MPs with Medcan Family Foundation 

Following the launch of a moving new awareness video, Medcan Family Foundation hosted a parliamentary event on Tuesday, 4 November, for cross-party MPs.

The film has now received over 1 million views, with more than 20,000 people visiting the action page to write to their MP. At the same time, attendance and engagement from MPs at the event were said to match that of larger, well-established organisations such as the Epilepsy Society. 

The charity also announced during the event the launch of a new randomised control trial into CBPMs in treatment-resistant epilepsy, for which it has secured first-stage funding to design and scope in collaboration with professionals experienced in both clinical trial development and cannabis.

Calling for urgent action with campaigners at End Our Pain

Patients and families from the campaign group End Our Pain have also been sharing their stories on social media, and over 600 people have signed an open letter calling for urgent government action on the lack of NHS access. 

Among other recommendations, campaigners say they want to see funding for NHS prescribing of CBPMs in chronic conditions and a public inquiry into the failure to implement the 2018 law.

Follow End Our Pain to hear more stories and support the campaign.

Celebrating exceptional contributions at the Cannabis Industry Council Awards 

On Thursday 6 November, the Cannabis Industry Council Awards returned to London for a second year, honouring exceptional contributions across every corner of the sector. From clinical excellence and scientific innovation to sustainability, patient advocacy, and the quiet dedication of those working behind the scenes, winners on the night included:

Dr Luisa Searle, Clinician of the Year
Dr Simon Erridge & Dr Mikael Sodergren, Contribution to Science
Guy Coxall, Social Impact
Jamie Bartley, Green Award
Leila Simpson, Unsung Hero

Patient-led education on medical cannabis and chronic pain

The international patient-led organisation We, The Patients, brought its educational event series on Medical Cannabis and Chronic Pain to London for the first time on Friday 7 November, in partnership with PatientsCann UK.

The one-day event was held at the historic venue, the Charterhouse, and for the first time in its 650 years of history, patients were permitted to medicate with cannabis inside the premises. Speaking after the event, organisers described it as a moment of “connection, recognition and hope for all patients”.

Exclusive insights and networking at Talman House 

The Talman Group brought together investors, innovators, and industry leaders for a day of insight and exchange at The Savoy in London on Monday, 10 November.

Designed for investors, the event delivered valuable perspectives on the latest market trends, regulatory developments, and emerging business opportunities across Europe and beyond. The event was described as an “outstanding success” with a thoughtfully curated agenda, expert-led discussions, and exclusive networking.

And still to come… 

Expert-led clinician education at Cannabis Health Symposium

Bringing Medical Cannabis Awareness Month to a close, the inaugural Cannabis Health Symposium will take place on Tuesday 25 November at Conway Hall, London.

The one-day, CPD-accredited event is designed to provide UK healthcare professionals with expert-led, clinically grounded education on cannabis-based medicinal products. The forum will offer practical insights and help clinicians build the confidence needed to safely and effectively integrate CBPMs into patient treatment protocols. 

Over the course of the day, attendees will hear expert-led presentations, clinical case studies, and gain practical guidance to obtain a deeper understanding of how medical cannabis can safely and effectively support patients with a range of health conditions.

Get your tickets here 

Source link